Wall Street Lifts Obesity Drug Targets for Eli Lilly and AbbVie as Medicare Coverage Expands
Analysts raised price targets for Eli Lilly and AbbVie as Medicare expands GLP-1 access. JPMorgan lifted Lilly to $1,400 from $1,300, citing Mounjaro and Zepbound strength. AbbVie targets were raised by multiple firms. From July 1, Medicare’s GLP-1 Bridge lowers Zepbound and Lilly’s Foundayo to about $50/month for eligible patients; Lilly guided FY revenue to $82B-$85B.
How this was made
The 30-second read
Why it matters
For LLY, the combination of a new JPMorgan target and a specific Medicare access expansion for its products (Zepbound and Foundayo) is a direct, time-sensitive catalyst. For ABBV, the Medicare policy is not directly linked to its products, so the impact is more indirect and driven by analyst PT changes.
Market read
Traders may reassess obesity-drug demand assumptions ahead of July 1 Medicare access expansion, with LLY receiving the most direct linkage to the policy and a fresh analyst upgrade.
What to watch
Analyst price targets can lag real-world uptake; actual utilization, payer restrictions beyond Bridge, and competitive GLP-1 pricing dynamics could temper the read-through.
Background
The article frames obesity-drug demand as accelerating due to a new Medicare GLP-1 Bridge initiative starting July 1, while highlighting fresh Wall Street price-target actions.
Ticker impact
JPMorgan raised Eli Lilly’s price target to $1,400 from $1,300 and reiterated overweight as Medicare GLP-1 coverage expands for Zepbound and Foundayo.
Bullish bias, with upside skew if analysts continue to model higher Medicare-driven demand.
The article ties a fresh analyst target change to a specific policy starting July 1 that lowers patient cost and expands eligible access.
The article notes AbbVie’s recent string of price target increases tied to its immunology franchise, alongside broader large-cap pharma strength.
Limited incremental upside versus LLY, unless further obesity read-through emerges.
The Medicare policy described is for Zepbound and Lilly’s oral pill, while ABBV is discussed mainly via immunology-driven strength and analyst PT changes.
Market effects
Medicare GLP-1 Bridge access expansion reinforces demand expectations for obesity drugs, likely supporting sentiment across GLP-1-focused pharma.
Primarily US demand-side catalyst via Medicare coverage.
Could strengthen global investor appetite for obesity franchises, though the policy is US-specific.
Counterpoint
Medicare Bridge eligibility is expected to be much smaller than the full 20 million Medicare-patient addressable market, so near-term demand uplift may be less than bulls imply.
Key entities
- companyEli Lilly
JPMorgan raised its price target to $1,400 from $1,300; Medicare GLP-1 Bridge makes Zepbound and its oral pill Foundayo available to eligible patients.
- companyAbbVie
Receives multiple analyst price-target increases in recent sessions, but the Medicare policy described is not attributed to AbbVie’s obesity exposure.
- policyMedicare GLP-1 Bridge initiative
Starting July 1, lowers patient cost for Zepbound and Foundayo to as little as $50 per month for eligible Medicare patients.
